FHTX (Foghorn Therapeutics) Additional Paid-In Capital: $578.62 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FHTX Foghorn Therapeutics Inc FHTX
70 GF Score
Price $4.79
GF Value $5.26
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Foghorn Therapeutics Additional Paid-In Capital?

Foghorn Therapeutics FHTX -0.93% 70 Additional Paid-In Capital is $578.62 Mil as of Jun. 2026. GuruFocus rates FHTX with a GF Score™ of 70/100 and a GF Value™ of $5.26 (Fairly Valued). The stock has 5 warning signs investors should review.


Foghorn Therapeutics's quarterly additional paid-in capital increased from Dec. 2025 ($523.94 Mil) to Mar. 2026 ($576.06 Mil) and increased from Mar. 2026 ($576.06 Mil) to Jun. 2026 ($578.62 Mil).

Foghorn Therapeutics's annual additional paid-in capital increased from Dec. 2023 ($395.20 Mil) to Dec. 2024 ($512.52 Mil) and increased from Dec. 2024 ($512.52 Mil) to Dec. 2025 ($523.94 Mil).

Foghorn Therapeutics Additional Paid-In Capital Related Terms

Foghorn Therapeutics Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Foghorn Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Foghorn Therapeutics Additional Paid-In Capital Chart

Foghorn Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
Get a 7-Day Free Trial 361.13 377.23 395.20 512.52 523.94

Foghorn Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 518.33 521.12 523.94 576.06 578.62
FHTX
70GF Score
Foghorn Therapeutics Inc FHTX
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Foghorn Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $578.62 Mil mean?
Foghorn Therapeutics (FHTX) has a Additional Paid-In Capital of $578.62 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Foghorn Therapeutics and its competitors.
Is Foghorn Therapeutics' Additional Paid-In Capital too high?
Foghorn Therapeutics' current Additional Paid-In Capital is $578.62 Mil. Overall, Foghorn Therapeutics has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Foghorn Therapeutics' Additional Paid-In Capital compare to LYEL and ZNTL?
Foghorn Therapeutics' Additional Paid-In Capital of $578.62 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Biotechnology company?
A good Additional Paid-In Capital depends on the Biotechnology industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Foghorn Therapeutics and its competitors. Foghorn Therapeutics's current Additional Paid-In Capital is $578.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Foghorn Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Foghorn Therapeutics (FHTX) is currently considered Fairly Valued. The stock's GF Value™ is $5.26, compared to a current price of $4.79 — trading 9% below its estimated fair value. The current Additional Paid-In Capital is $578.62 Mil. Foghorn Therapeutics' overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Foghorn Therapeutics (FHTX), the current Additional Paid-In Capital is $578.62 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Foghorn Therapeutics (FHTX) Overvalued in 2026?

Based on GuruFocus' analysis, Foghorn Therapeutics stock appears to be undervalued. The current stock price of $4.79 is trading 9% below its estimated GF Value™ of $5.26. GuruFocus considers Foghorn Therapeutics to be Fairly Valued.

Key valuation signals for FHTX:

  • Additional Paid-In Capital: $578.62 Mil
  • GF Value™: $5.26 vs. price of $4.79 (9% below fair value)
  • GF Score™: 70/100 with 5 warning signs

No single metric tells the full story. See the FHTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Foghorn Therapeutics Business Description

Address 99 Coolidge Avenue, Suite 500, Watertown, MA, USA, 02472
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
70GF Score

Get the complete analysis for FHTX

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.79
Price
$5.26
GF Value